Cheng-Hung Chien

Cheng-Hung Chien


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
LCLi-Wei Chen
Li-Wei Chen
PHPin-Ren Huang
Pin-Ren Huang
CCCheng-Hung Chien
Cheng-Hung Chien
CLChih-Lang Lin
Chih-Lang Lin
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien
Nonalcoholic fatty liver disease (NAFLD) is now a global liver disease. The fatty liver index (FLI), which is calculated by the equation comprising waist circumference, body mass index (BMI), triglyceride, and gamma glutamyl transpeptidase (GGT), is frequently used for hepatic steatosis evaluation. This study aimed to evaluate the optimal cut-off point of FLI to select subjects for abdominal ultrasonography (US) screening for NAFLD in the community. From August 2013 to August 2016, a community-based study was performed in the northeastern region of Taiwan. All subjects participated in a demographic survey, blood testing, and abdominal US. The formula for FLI is: FLI = [e 0.953×loge (TG)+0.139×BMI+0.718×loge (GGT) +0.053×waist circumference-15.745]/[1 + e 0.953×loge (TG)+0.139×BMI+0.718×loge (GGT)+0.053×waist circumference-15.745] × 100. A total of 1371 subjects were included (746 in NAFLD group and 625 in the control group). The mean ages were 57.1 years in the control group and 56.3 years in the NAFLD group. The optimal cut-off points of FLI to discriminate fatty liver by abdominal US were 20 in male and 10 in female (sensitivity 80.3% and 76.1%; specificity 66.9% and 65.5%, respectively). FLI was correlated with the severity of fatty liver by abdominal US, predict fat component percent and NAFLD fibrosis score, especially in the female subjects. FLI could be a tool to select subjects for abdominal US in a large community survey. The cut-off point of FLI might be set to 10 for female and 20 for male subjects, to increase the sensitivity for selecting subjects to receive abdominal US.

16 July 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
LCLi-Wei Chen
Li-Wei Chen
CCCheng-Hung Chien
Cheng-Hung Chien
SKSheng-Fong Kuo
Sheng-Fong Kuo
CYChia-Ying Yu
Chia-Ying Yu
CLChih-Lang Lin
Chih-Lang Lin
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien
This study aimed to evaluate the association between serum vitamin D levels and nonalcoholic fatty liver disease (NAFLD) parameters, such as metabolic syndrome (MS), inflammatory cytokines (tumor necrosis factor, high sensitive C-reactive protein) and adipokines (adiponectin, leptin). From August 2013 to August 2016, a community-based study was performed in the north-eastern region of Taiwan. All subjects received a demographic survey, blood testing and abdominal ultrasonography (US). The vitamin D level was evaluated by quartile divide or used the classification of deficiency (< 20 ng/ml), insufficiency (20–30 ng/ml) and sufficiency (> 30 ng/ml). Subjects were divided into NAFLD group and normal control (subjects number = 564 in each group) following abdominal US study and matching age and gender. The mean age was 57.1 years in NAFLD group and 57.5 in control group. Subjects in NAFLD group had a lower mean vitamin D than those in the control group (28.5 ± 9.5 ng/ml vs. 29.9 ± 10.2 ng/ml, P = 0.018). Subjects with serum vitamin D deficiency or insufficiency had higher odds for MS than those with sufficient vitamin D levels [deficiency vs. sufficiency, adjusted odds ratio (aOR) =1.860 (95% CI = 1.234–2.804), P = 0.003; insufficiency vs. sufficiency, aOR = 1.669 (95% CI = 1.237–2.251), P = 0.001]. Similarly, subjects in the lowest quartile of vitamin D had higher odds for MS than those in the highest quartile of vitamin D (aOR = 2.792, 95% CI = 1.719–4.538, P < 0.001). Vitamin D level was positively correlated with age and male, but negatively correlated with serum leptin level. Subjects with low vitamin D level had higher odds for MS, but higher levels of leptin, compared to those with high vitamin D levels.

Verified
Journal Article
Open access
PDF file
CTChien Tsuo-Hsuan
Chien Tsuo-Hsuan
CLChih-Lang Lin
Chih-Lang Lin
LCLi-Wei Chen
Li-Wei Chen
CCCheng-Hung Chien
Cheng-Hung Chien
CHChing-Chih Hu
Ching-Chih Hu
Patients with non-alcoholic fatty liver disease (NAFLD) share similar pathophysiologies to those of patients with alcohol liver disease. Alcoholic metabolic enzyme-related genes (alcohol dehydrogenase 1B (ADH1B) and aldehyde dehydrogenase 2 (ALDH2)) may be associated with pathophysiology in NAFLD patients. In this study, the association between ADH1B/ALDH2 gene polymorphism and serum metabolic factors, body statures, and hepatic steatosis/fibrosis status was evaluated in patients with NAFLD. Using biochemistry data, abdominal ultrasonography, fibrosis evaluation (Kpa), and steatosis evaluation (CAP), ADH1B gene SNP rs1229984 and ALDH2 gene SNP rs671 polymorphism were analyzed in sixty-six patients from 1 January 2022 to 31 December 2022. The percentage of the mutant type (GA + AA) was 87.9% (58/66) in the ADH1B allele and 45.5% (30/66) in the ALDH2 allele. Patients with the mutant-type ADH1B/ALDH2 allele had higher values of alanine aminotransferase (ALT) than the wild type (β = 0.273, p = 0.04). No association was observed between body mass index, serum metabolic factors (sugar and lipid profile), CAP, kPa, and ADH1B/ALDH2. A high proportion of the mutant-type ADH1B allele (87.9%) and ALDH2 allele (45.5%) was observed in patients with NAFLD. No association was observed between ADH1B/ALDH2 allele, BMI, and hepatic steatosis/fibrosis. Patients with the mutant-type ADH1B/ALDH2 allele had higher values of ALT than those with the wild type.

28 August 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
YLYuh-Ying Liu
Yuh-Ying Liu
CLChih-Lang Lin
Chih-Lang Lin
CWCheng-Hao Weng
Cheng-Hao Weng
PCPei-Hung Chang
Pei-Hung Chang
CCCheng-Hung Chien
Cheng-Hung Chien
CHChing-Chih Hu
Ching-Chih Hu
Background: Nucleos(t)ide analogues (NUCs) were proved to reduce hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients, but data were limited on their efficacy in cirrhotic CHB patients. Methods: A total of 447 cirrhotic CHB patients treated with tenofovir/entecavir were retrospectively analyzed and divided into HCC (n = 48) and non-HCC (n = 399) groups. The median follow-up period was 62.1 months. Results: A total of 48 patients (10.7%) developed HCC during surveillance. The annual incidence rate of HCC was 2.04 per 100 person-years. The cumulative incidence of HCC was 0.9%, 9.8%, and 22.1% at 1, 5, and 10 years, respectively. Significant predictors for HCC identified using a multiple Cox regression analysis were age ≥50 years (hazard ratio (HR): 2.34) and α-fetoprotein (AFP) ≥8 ng/mL (HR: 2.05). The incidence rate of HCC was 8.67-fold higher in patients with age ≥50 years and AFP ≥8 ng/mL (3.14 per 100 person-years) than those with age <50 years and AFP <8 ng/mL (0.36 per 100 person-years). Conclusions: Cirrhotic CHB patients with age <50 years and AFP <8 ng/mL had the lowest annual incidence of HCC. However, those with age ≥50 years or/and AFP ≥8 ng/mL had a significantly higher risk for HCC development and warrant a careful surveillance schedule.

29 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CCCheng-Hung Chien
Cheng-Hung Chien
LCLi-Wei Chen
Li-Wei Chen
CLChih-Lang Lin
Chih-Lang Lin
SCSu-Wie Chang
Su-Wie Chang
YSYu-Chiau Shyu
Yu-Chiau Shyu
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien
The objective of this study was to determine whether awareness of hepatitis B virus (HBV) serostatus was discordant with metabolic syndrome (MetS) among people with chronic HBV infection. We conducted a community-based study in four Taiwanese districts. A total of 3493 adult participants were recruited. Participants who were hepatitis B surface antigen (HBsAg) seropositive and had self-reported HBV infection were considered aware of hepatitis B (aHB); those who denied a history of HBV infection were considered unaware of hepatitis B (uaHB). Among the 454 participants who were HBsAg seropositive, 275 (60.6%) were aHB and 179 (39.3%) were uaHB. Hypertriglyceridemia showed significant inverse association with HBsAg seropositive, especially among those who were aHB. Insulin resistance was significantly, positively associated with HBsAg seropositive, especially among participants who were uaHB. Those who were uaHB had a higher risk of central obesity, hyperglycemia, insulin resistance, and MetS than those who were aHB (odds ratio = 2.33, 1.64, 2.15, 1.85, respectively, all p < 0.05). The association among the prevalence of MetS, its individual components and HBsAg seropositivity varies according to awareness of HBV infection. It is important to recognize an individual’s risk for MetS, especially who were unaware of HBV infection.

Verified
Journal Article
Open access
PDF file
XHxie cheng han
xie cheng han
LCLi-Wei Chen
Li-Wei Chen
CLChih-Lang Lin
Chih-Lang Lin
CHChing-Chih Hu
Ching-Chih Hu
CCCheng-Hung Chien
Cheng-Hung Chien
Elevated serum ferritin and uric acid levels are common in patients with fatty liver disease. This study assessed the association between serum ferritin and uric acid levels and liver fibrosis in subjects with lean metabolic dysfunction-associated fatty liver disease (MAFLD). This cross-sectional study used data from a community screening examination for metabolic syndrome from December 2018 to September 2019 at Keelung Chang Gung Memorial Hospital. Subjects with lean MAFLD were defined as those with a body mass index (BMI) < 23 kg/m2 and hepatic steatosis according to the MAFLD criteria. A total of 182 lean subjects were included and were divided into lean MAFLD and lean healthy groups. Serum ferritin and uric acid concentrations were positively correlated with liver fibrosis, regardless of whether FIB-4, APRI, or NFS were used as references. Univariate logistic regression analysis showed that age and uric acid were associated with advanced liver fibrosis. After adjusting for potential confounders, only uric acid level was statistically significant in predicting the advanced liver fibrosis (OR = 6.907 (1.111–42.94), p = 0.038) in the lean MAFLD group. We found that an elevated serum uric acid level is an independent factor associated with advanced liver fibrosis in lean MAFLD subjects by noninvasive fibrosis scores.